Answers are grounded in this paper and cite their sources.
Progression independent of relapse activity (PIRA) drives irreversible disability in multiple sclerosis, but its immunological basis is incompletely understood. We profiled peripheral myeloid cells from untreated individuals with relapsing-remitting or progressive multiple sclerosis and healthy controls using single-cell RNA sequencing, flow cytometry and untargeted lipidomics. We identified SDC2+ classical monocytes with a foam-like signature that were enriched in progressive disease, increased in patients undergoing PIRA and associated with Expanded Disability Status Scale scores. These cells exhibited increased LPCAT1 and reduced PLA2G4A expression, accompanied by phosphatidylcholine accumulation and lysophosphatidylcholine depletion, consistent with altered Lands-cycle phospholipid remodeling. They also expressed peroxisomal, iron-handling and ferroptosis-associated programs. Human CNS multi-omic datasets revealed analogous SDC2+LPCAT1+ foam cells enriched in chronic active/inactive white matter and subpial lesions, whereas remyelinating lesions showed partial normalization of this lipidomic signature. These findings define a shared systemic myeloid program associated with chronic, relapse-independent progression in multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Weiner et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: